Riboswitch Platform (CAR-T)

About MeiraGTx

MeiraGTx is a clinical-stage biotech focused on translating advanced genetic medicine into transformative therapies for diseases with high unmet need. Its strategy is built on a fully integrated platform combining novel vector engineering, precision gene control via its riboswitch technology, and in-house GMP manufacturing. Key achievements include a late-stage pipeline with Breakthrough Therapy designation for its xerostomia program and a major strategic collaboration with Eli Lilly in ophthalmology, positioning the company for significant value inflection.

Therapeutic Areas